Yasin Keshvargar
Advises issuers and underwriters on a broad range of capital markets transactions. Recognized by Chambers USA and named a 2021 “Rising Star” by Law360.
U.S. and non-U.S. issuers and underwriters seek Yasin’s advice on a broad range of capital markets transactions, including initial public offerings and other equity offerings, public and private high-yield, investment-grade and convertible debt financings, restructurings and cross-border transactions. Yasin also advises clients ranging from early-stage privately held companies to well-known seasoned issuers on governance, SEC reporting, strategic transactions and other corporate law matters.
He is recognized for his capital markets work by Chambers USA and was named a “Rising Star” in capital markets by Law360 in 2021.
His practice spans a variety of industries, including biotech, consumer products and retail, fintech, technology, and healthcare and life sciences.
In 2020, Yasin served as co-leader of Davis Polk’s cross-practice, cross-border coronavirus task force, work for which he was named a “Crisis Leadership Trailblazer” by the National Law Journal.
Experience highlights
IPOs
- Initial public offerings by US emerging growth companies, including Atea, Akoya, Ayala, Beam Therapeutics, Biodesix, Cvent, Cyteir, Dream Finders Homes, Evolent Health, European Biotech Acquisition Co., Generation Bio, Jounce Therapeutics, Legend Biotech, loanDepot, Magenta Therapeutics, Ophthotech, Progyny, Solid Biosciences, Stoke Therapeutics, Terns Pharmaceuticals and UiPath
- Initial public offerings by foreign private issuer emerging growth companies including Ablynx (Belgium), ADC Therapeutics (Switzerland), Advanced Accelerator Applications (France), Avolon (Ireland), BioNTech, the highest-valued European biotech IPO (Germany), GeoPark (Argentina), GH Research (Ireland), Gracell Biotechnologies, the first operating company IPO of 2021 (Cayman Islands), Immunocore (United Kingdom), Innate Pharma (France), Inventiva (France), Molecular Partners (Switzerland), On Holding (Switzerland) and SOPHiA GENETICS (Switzerland)
- Initial public offerings by non-emerging growth companies, including loanDepot, Grupo Aval, the largest U.S. IPO by a Latin American issuer in 2014, and Hudson News
Other Equity Offerings
- Numerous representations of issuers and placement agents in connection with pre-IPO private placements, PIPEs, forward sale transactions and ATM programs
- Completed the largest secondary offering of common stock in history ($16.0 billion common equity offering for a telecommunications company)
- Follow-on or secondary offerings by Advanced Accelerator Applications, Applied Genetic Technologies, Bioxcel Therapeutics, Cvent, Energizer, Evolent Health, Hilton, Perion Network, PTC Therapeutics, ShakeShack and Southwestern Energy
- Rights offerings by BioNTech, Liberty Media and a national telecommunications company
Investment- and High-Grade Debt
- Offerings by Eastman, Heineken, Mylan, Evolent Health, PTC Therapeutics, Stanley Black & Decker and Walgreens
High Yield Debt
- High-yield debt offerings by Adtalem, Energizer, Western Refining, NCI Building Systems, Murphy, Spirit Airlines and XPO Logistics
Convertible Debt
- Convertible debt offerings by Assertio, Evolent Health, Integra LifeSciences, Ormat, Southwestern Energy and PTC Therapeutics
Liability Management
- Transactions for ADC Therapeutics, Beazer Homes, Evolent Health, Energizer, Grupo Aval, Murphy Oil, Walgreens and XPO Logistics
Insights
Credentials
Recognition
Chambers USA – Capital Markets: Debt & Equity: Eastern United States
Law360 – “Rising Star: Capital Markets,” 2021
National Law Journal – “Crisis Leadership Trailblazer,” 2020
Education
- first-class honours
- Clifford Chance Prize for Outstanding Performance
Professional history
- Partner, 2019-present
- Counsel, 2017-2019
- Davis Polk since 2008
Qualifications and admissions
- State of New York